Trials / Unknown
UnknownNCT03099278
Ezetimibe for Patients With Chronic Hepatitis D
- Status
- Unknown
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 20 (estimated)
- Sponsor
- Ziauddin Hospital · Academic / Other
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
Ezetimibe possesses pharmacophore features to inhibit NTCP, the receptor required for HBV and HDV hepatocyte entry that include two hydrophobes and one hydrogen bond acceptor. Therapy with Ezetimibe may lead to decline in hepatitis D virus levels. The aim of the study is to evaluate the utility of Ezetimibe in patients with chronic HDV infection
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Ezetimibe | Ezetimibe 20 mg oral daily |
Timeline
- Start date
- 2017-01-01
- Primary completion
- 2017-06-01
- Completion
- 2017-10-01
- First posted
- 2017-04-04
- Last updated
- 2017-04-04
Locations
1 site across 1 country: Pakistan
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT03099278. Inclusion in this directory is not an endorsement.